Obstetrics & Gynecology Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Obstetrics & Gynecology 1984;63:557-560
© 1984 by The American College of Obstetricians and Gynecologists
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LOVECCHIO, J L
Right arrow Articles by FENTON, A N
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LOVECCHIO, J L
Right arrow Articles by FENTON, A N

Treatment of Advanced or Recurrent Endometrial Adenocarcinoma With Cyclophosphamide, Doxorubicin, Cis-Platinum, and Megestrol Acetate

J L LOVECCHIO, MD, H E AVERETTE, MD, M. LICHTINGER, MD, P A TOWNSEND, MD, R W GIRTANNER, MD, A N FENTON, MD and A N FENTON, MD

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Miami School of Medicine, Miami, Florida

Abstract

A prospective clinical trial using combination chemotherapy consisting of cyclophosphamide, doxorubicin, cis-Platinum and megestrol acetate (CAP-M) was initiated to study its effect on advanced or recurrent endometrial adenocarcinoma. Fifteen patients were clinically evaluable. Nine patients (60%) demonstrated an overall objective clinical response resulting in either complete regression of disease (33%) or a reduction in tumor size. For all responders the mean progression free interval was eight months, with a range of five to 11 months. Similarly, a mean survival time of 12 months with a range of five to 21 months was observed. An additional four patients showed no progressive disease for a mean of seven months duration. Reversible cis-Platinum-induced nephrotoxicity occurred in two patients. This is the first reported series of endometrial cancer patients using nonhormonal cytotoxic agents, including cis-Platinum, in conjunction with a progestin. This preliminary experience is encouraging and appears worthy of further clinical evaluation.




This article has been cited by other articles:


Home page
 Ann OncolHome page
C. Humber, J. Tierney, R. Symonds, M Collingwood, J Kirwan, C Williams, and J. Green
Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration
Ann. Onc., March 1, 2007; 18(3): 409 - 420.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1984 by the American College of Obstetricians and Gynecologists.